Apollomics has articulated a clear vision for the utilization of the net proceeds from this financing round. Apollomics Inc. (Nasdaq: APLM), a burgeoning force in the clinical-stage biopharmaceutical arena, has recently announced a strategic private investment in public equity (PIPE) financing. This bold step is poised to inject approximately $6 million in gross proceeds into the company, prior to the ded...
$Apollomics(APLM.US)$Apollomics Completed Patient Enrollment For The Uproleselan (Apl-106) Phase 3 Bridging Study In China – Topline Data Expected In The First Half Of 2025
$Apollomics(APLM.US)$Apollomics Completes Enrollment In Phase 3 Bridging Study Of Uproleselan (APL-106) Added To A Standard Chemotherapy Regimen In Chinese Patients With Relapsed/Refractory Acute Myeloid Leukemia Benzinga· 3 mins ago
$Apollomics(APLM.US)$still have a bag on this. ill a erage down and aim to get out. misplayed this. poor entry and didnt exit at gains. win some lose some.
Apollomics股票討論區
Apollomics Inc. (Nasdaq: APLM), a burgeoning force in the clinical-stage biopharmaceutical arena, has recently announced a strategic private investment in public equity (PIPE) financing. This bold step is poised to inject approximately $6 million in gross proceeds into the company, prior to the ded...
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Benzinga· 3 mins ago
暫無評論